MMV646

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
MoA
  • Inhibition of haemazoin formation
Key features
  • Highly potent against P. falciparum and P. vivax field isolates
  • Very low propensity to develop resistance in vitro
  • Favorable pharmacokinetic profiles in all species tested
  • Single dose cure in severe combined immunodeficiency (SCID) mouse models
Challenges
  • Low solubility, likely food effect
  • Potent inhibition of CYP2D6 (possible drug-drug-interaction)
Status
  • Preclinical development
Next milestone
  • Scale-up synthesis and conduct Good Laboratory Practice (GLP) safety studies
Previously
  • JPC-3210 researched in collaboration with the Jacobus Pharmaceutical Company
MMV Project Director
  • Dr Andrew Slade